Genmab A/S (GNMSF)
USD 203.33
(0.0%)
USD 203.33
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.92 Billion DKK | 28.67% |
| 2022 | 8.23 Billion DKK | 50.77% |
| 2021 | 5.46 Billion DKK | 43.87% |
| 2020 | 3.79 Billion DKK | 39.22% |
| 2019 | 2.72 Billion DKK | 65.85% |
| 2018 | 1.64 Billion DKK | 61.06% |
| 2017 | 1.02 Billion DKK | 33.8% |
| 2016 | 763.28 Million DKK | 89.56% |
| 2015 | 402.66 Million DKK | -31.19% |
| 2014 | 585.2 Million DKK | -1.53% |
| 2013 | 594.31 Million DKK | -1.16% |
| 2012 | 601.31 Million DKK | 786.23% |
| 2011 | 67.85 Million DKK | -57.66% |
| 2010 | 160.25 Million DKK | -85.22% |
| 2009 | 1.08 Billion DKK | -19.4% |
| 2008 | 1.34 Billion DKK | 39.15% |
| 2007 | 966.67 Million DKK | 59.05% |
| 2006 | 607.76 Million DKK | 15.45% |
| 2005 | 526.42 Million DKK | 220.42% |
| 2004 | -437.17 Million DKK | -206.49% |
| 2003 | 410.53 Million DKK | -6.73% |
| 2002 | 440.17 Million DKK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.39 Billion DKK | 13.15% |
| 2024 Q1 | 3.15 Billion DKK | 9.54% |
| 2023 Q3 | 2.92 Billion DKK | 8.37% |
| 2023 Q1 | 2.41 Billion DKK | -5.66% |
| 2023 FY | 10.6 Billion DKK | 28.67% |
| 2023 Q2 | 2.7 Billion DKK | 11.75% |
| 2023 Q4 | 2.88 Billion DKK | -1.54% |
| 2022 FY | 8.23 Billion DKK | 50.77% |
| 2022 Q2 | 1.91 Billion DKK | 19.31% |
| 2022 Q1 | 1.6 Billion DKK | -11.33% |
| 2022 Q3 | 2.15 Billion DKK | 12.58% |
| 2022 Q4 | 2.56 Billion DKK | 18.83% |
| 2021 FY | 5.46 Billion DKK | 43.87% |
| 2021 Q4 | 1.81 Billion DKK | 27.46% |
| 2021 Q3 | 1.42 Billion DKK | 19.83% |
| 2021 Q2 | 1.18 Billion DKK | 12.96% |
| 2021 Q1 | 1.04 Billion DKK | -9.33% |
| 2020 Q3 | 866 Million DKK | -9.22% |
| 2020 FY | 3.79 Billion DKK | 39.22% |
| 2020 Q4 | 1.15 Billion DKK | 33.6% |
| 2020 Q2 | 954 Million DKK | 16.2% |
| 2020 Q1 | 821 Million DKK | 4.56% |
| 2019 Q3 | 689.11 Million DKK | 8.22% |
| 2019 Q2 | 636.74 Million DKK | 3.21% |
| 2019 Q1 | 616.93 Million DKK | 19.83% |
| 2019 Q4 | 785.2 Million DKK | 13.95% |
| 2019 FY | 2.72 Billion DKK | 65.85% |
| 2018 Q2 | 374.63 Million DKK | 4.95% |
| 2018 Q1 | 356.96 Million DKK | 13.51% |
| 2018 FY | 1.64 Billion DKK | 61.06% |
| 2018 Q4 | 514.83 Million DKK | 29.22% |
| 2018 Q3 | 398.42 Million DKK | 6.35% |
| 2017 FY | 1.02 Billion DKK | 33.8% |
| 2017 Q4 | 314.47 Million DKK | 18.6% |
| 2017 Q2 | 236.93 Million DKK | 15.74% |
| 2017 Q3 | 265.14 Million DKK | 11.91% |
| 2017 Q1 | 204.7 Million DKK | -6.77% |
| 2016 Q3 | 177.82 Million DKK | -16.14% |
| 2016 FY | 763.28 Million DKK | 89.56% |
| 2016 Q4 | 219.58 Million DKK | 23.48% |
| 2016 Q1 | 153.83 Million DKK | -22.82% |
| 2016 Q2 | 212.04 Million DKK | 37.84% |
| 2015 Q1 | -66.16 Million DKK | -142.8% |
| 2015 Q3 | 135.08 Million DKK | 0.49% |
| 2015 Q2 | 134.42 Million DKK | 303.18% |
| 2015 Q4 | 199.31 Million DKK | 47.54% |
| 2015 FY | 402.66 Million DKK | -31.19% |
| 2014 Q3 | 132.19 Million DKK | -10.49% |
| 2014 FY | 585.2 Million DKK | -1.53% |
| 2014 Q4 | 154.58 Million DKK | 16.94% |
| 2014 Q2 | 147.69 Million DKK | -2.01% |
| 2014 Q1 | 150.72 Million DKK | -7.38% |
| 2013 Q3 | 144.96 Million DKK | -7.05% |
| 2013 FY | 594.31 Million DKK | -1.16% |
| 2013 Q2 | 155.95 Million DKK | 19.35% |
| 2013 Q1 | 130.66 Million DKK | -23.58% |
| 2013 Q4 | 162.72 Million DKK | 12.25% |
| 2012 Q1 | 15.1 Million DKK | -0.73% |
| 2012 Q4 | 170.99 Million DKK | 19.47% |
| 2012 FY | 601.31 Million DKK | 786.23% |
| 2012 Q2 | 16.22 Million DKK | 7.44% |
| 2012 Q3 | 143.13 Million DKK | 782.01% |
| 2011 Q1 | 17.37 Million DKK | -42.3% |
| 2011 Q3 | 17.49 Million DKK | -1.55% |
| 2011 Q2 | 17.76 Million DKK | 2.26% |
| 2011 FY | 67.85 Million DKK | -57.66% |
| 2011 Q4 | 15.21 Million DKK | -13.02% |
| 2010 Q4 | 30.11 Million DKK | 12.49% |
| 2010 Q2 | 263.6 Million DKK | 4.18% |
| 2010 Q1 | 253.02 Million DKK | -73.89% |
| 2010 FY | 160.25 Million DKK | -85.22% |
| 2010 Q3 | 26.77 Million DKK | -89.84% |
| 2009 Q1 | 286.63 Million DKK | 0.0% |
| 2009 FY | 1.08 Billion DKK | -19.4% |
| 2009 Q3 | 40.33 Million DKK | -83.9% |
| 2009 Q4 | 969.17 Million DKK | 2302.56% |
| 2009 Q2 | 250.49 Million DKK | -12.61% |
| 2008 FY | 1.34 Billion DKK | 39.15% |
| 2007 FY | 966.67 Million DKK | 59.05% |
| 2006 FY | 607.76 Million DKK | 15.45% |
| 2005 FY | 526.42 Million DKK | 220.42% |
| 2004 FY | -437.17 Million DKK | -206.49% |
| 2003 FY | 410.53 Million DKK | -6.73% |
| 2002 FY | 440.17 Million DKK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -12490.886% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -222087.745% |
| SQZ Biotechnologies Company | 85.61 Million USD | -12662.354% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -36874.25% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -29229.762% |
| Mesoblast Limited | 5.9 Million USD | -185040.63% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -727445.594% |
| Genus plc | 147.7 Million USD | -7298.104% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -124364.162% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -814408.645% |
| Marizyme, Inc. | 19.23 Million USD | -56693.635% |
| ContraFect Corporation | 56.88 Million USD | -19107.58% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -130934.896% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -247752.415% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -738833.912% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -374595.455% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -391498.638% |
| MultiCell Technologies, Inc. | 567.42 USD | -1925733924.18% |
| Accustem Sciences Inc. | 3.74 Million USD | -291565.187% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -12613.945% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2053994.089% |
| Q BioMed Inc. | 3.43 Million USD | -317857.021% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -44112.017% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2804816.24% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -415767.117% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1098994.532% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | -4745.87% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -162552.212% |
| Skye Bioscience, Inc. | 13.54 Million USD | -80556.65% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -533261.318% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 43708100.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -216617.665% |
| IMV Inc. | 37.7 Million USD | -28877.002% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -68150.083% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -595346.012% |
| GB Sciences, Inc. | 1.42 Million USD | -769131.311% |
| Alpha Cognition Inc. | 9.7 Million USD | -112484.476% |
| HST Global, Inc. | 140.9 Thousand USD | -7754660.232% |
| CSL Limited | 3.44 Billion USD | -216.816% |
| Halberd Corporation | 74.84 Thousand USD | -14599990.858% |
| Enzolytics Inc. | 2.17 Million USD | -501251.911% |
| Resverlogix Corp. | 12.71 Million USD | -85858.15% |
| Affymax, Inc. | 39.38 Million USD | -27643.361% |
| SYBLEU INC | 160.87 Thousand USD | -6792087.772% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -299211.887% |
| argenx SE | 1.53 Billion USD | -612.539% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -18923.329% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1046547.51% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -691764.717% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -320812.405% |
| AVAX Technologies, Inc. | 7.31 Million USD | -149374.766% |
| Zenith Capital Corp. | 8.94 Million USD | -122084.949% |
| Genscript Biotech Corporation | 825.34 Million USD | -1223.933% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -62723050.221% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -444934.185% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -6370994.228% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -10900.686% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -620865.881% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -553997.952% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -585996.108% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -100452.13% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -568746.159% |
| BioStem Technologies, Inc. | 22.97 Million USD | -47460.802% |
| ONE Bio Corp. | 6.44 Million USD | -169471.433% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -6020783.269% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -818137.708% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -971266.598% |
| Agentix Corp. | 1.37 Million USD | -796470.236% |
| LadRx Corporation | 3.81 Million USD | -286563.146% |
| Cell Source, Inc. | 4.32 Million USD | -252527.189% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2629876.485% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1183103.214% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1183103.214% |
| NovAccess Global Inc. | 2.46 Million USD | -442869.546% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -454257.583% |
| Itoco Inc. | 919.14 Thousand USD | -1188724.807% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -257708.699% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -976396.872% |
| Kadimastem Ltd | 2.41 Million USD | -453281.42% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -4174876.884% |
| CytoDyn Inc. | 18.05 Million USD | -60410.577% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -43414417.859% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1970340.685% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -4964957.843% |
| Qrons Inc. | 643.67 Thousand USD | -1697490.562% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -769519.775% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -489926.589% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1645532.53% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -601501.039% |
| International Stem Cell Corporation | 5.27 Million USD | -207204.117% |
| Bioxytran, Inc. | 3.82 Million USD | -285936.113% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -20757090.076% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -53713708.19% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -30030.149% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -675239.926% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1484879.649% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -351137.544% |
| Neutra Corp. | 243.82 Thousand USD | -4481466.395% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -62493.802% |
| PureTech Health plc | 144.59 Million USD | -7456.865% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -53228.744% |
| IXICO plc | 4.7 Million USD | -232043.616% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -124112.8% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -9179.988% |
| CSL Limited | 3.89 Billion USD | -180.683% |
| Cellectis S.A. | 97.32 Million USD | -11127.908% |